Recently, the Office of the National Leading Group for the Recognition and Management of High-tech Enterprises has disclosed the list of high-tech enterprises submitted by Zhejiang Province's recognition agency in the 2024 annual report.METiS TechBio Successfully Selected and Officially Recognized as a "National High-Tech Enterprise."This time, being awarded the title of National High-tech Enterprise is a high recognition of METiS TechBio's comprehensive strength in technological innovation capabilities, R&D investment, and the transformation of scientific and technological achievements. This honor fully demonstrates METiS TechBio's outstanding performance and potential in the field of technological innovation.
As a pioneer in the "AI + Drug Delivery" field,METiS TechBio has continuously made breakthroughs in technology research and development, overcoming challenges such as data scarcity and the lack of precedents for algorithms. It has independently developed groundbreaking artificial intelligence and computational simulation algorithms ranging from ionizable lipid generation and design to LNP (lipid nanoparticles) nanomaterial design and simulation. By integrating globally leading high-throughput experimental techniques and animal validation platforms, the company has successfully built a robust data and algorithmic barrier, achieving breakthrough progress in nanomaterial design and drug delivery.In addition, METiS TechBio keeps up with the cutting-edge advancements in artificial intelligence, integrating large models and generative AI technology to create pioneering solutions.METiS LipidLM Lipid Language ModelAndPhatGPT Lipid Generation Model, building a million-level lipid database and achieving remarkable success in breaking through international patent barriers. Through innovative molecular simulation technology, the company has been able to comprehensively simulate the microscopic processes of LNPs in vivo and in vitro. Combined with a world-class experimental validation platform, it has successfully developed multi-organ targeted nanomaterials, promoting the application of AI technology in the field of nanomaterials.The recognition as a "National High-tech Enterprise" is not only an affirmation of METiS TechBio's current achievements but also an encouragement for future development. METiS TechBio will continue to uphold the original intention of technological innovation, promote the continuous upgrading of "AI + drug delivery" technology, empower the development of the global pharmaceutical industry, and contribute to the cause of human health.
Learn More About METiS TechBio
